Table 2.

Relative advantages and disadvantages of each approach to haploBMT

Clinical outcome	T-cell depletion	GIAC protocol	PTCy
Engraftment	2–3	1	2–3
Acute GVHD	1	3	2
Chronic GVHD	1–2	3	1–2
Infection/deaths from infection	3	2	1
Nonrelapse mortality	3	2	1
Relapse	2–3	1	2–3

1 indicates most favourable; 2, intermediate; 3, least favourable. When more definitive ratings are unclear, a range is shown with the probable rating indicated in bold. Ratings take into account the findings of the available published studies (Table 1), but are unable to account for many factors that influence outcomes, such as differences between studies in patient characteristics or the malignant disease types, features or pretransplantation remission status.

Abbreviations: GVHD, graft-versus-host disease; haploBMT, human leukocyte antigen-haploidentical allogeneic blood or bone-marrow transplantation; PTCy, post-transplantation cyclophosphamide.